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The insulin like growth factor receptor subtype 1(IGF-1R) plays an important role in cancers transfor-
mationandprogression. Theaim is to investigate the effects of sunitinib on IGF-1R cell signaling trans-
duction, especially on receptor phosphorylation and ubiquitination. In HEK293 cells, IGF-1R signaling
pathwaysare activated in response to IGF-1,which inducesobviousphosphorylationsof receptor tyro-
sine and Akt, ERK. However, the phosphorylations of receptor tyrosine, Akt and ERK were signiﬁcant
inhibited by sunitinib. We found that both IGF-1 and sunitinib obviously down regulated the IGF-1R
expression. For analysis the ubiquitination, HEK293 cells were simulated with 100 ng/ml IGF-1 or
10 nM sunitinib for 10 min after serum starvation for 24 h. Both IGF-1 and sunitinib could obviously
induce the IGF-1R ubiquitination at 10 min compared with control (only serum free, no stimulation),
indicating IGF-1 and sunitinib down-regulate the IGF-1R by increasing the receptor degradation
through ubiquitination dependent proteasome pathway. We also found that MDM2 combined to
IGF-1R in response to sunitinib stimulation. To conﬁrm it, HEK293 cells were transfectedwith human
HA-MDM2 (+MDM2) or siRNA toMDM2 (MDM2). Following 24 h serum starvation, cells were stimu-
lated with 10 nM sunitinib for 10 min. In over-expressed MDM2 cells, IGF-1R wasmore ubiquitinated
than that in mock-transfected cells (control), and no ubiquitination in MDM2 cells. These results
mean that sunitinib mediates ubiquitination of IGF-1R dependent on MDM2. In summary, sunitinib
could block signaling transduction and mediate degradation of IGF-1R.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
The insulin like growth factor type 1receptor (IGF-1R) belongs to
transmembrane, receptor tyrosine kinases families, which is known
plays a crucial role in the development and progression of human
cancers. Overexpression of IGF-1R is observed in many human
malignancies [1], often involved in worse prognosis [2,3] The IGF-
1R is a prominent target for anti-cancer therapy and the downregu-
lation of its activity has been shown to inhibit the growth of many
types of human tumor cells. Many researches on IGF-1R function
inhibition have been investigated during the past years. The IGF-
1Rmonoclonal antibodies,whichmediate receptor downregulation,
have been encouraging in cancer cell lines [4,5] and xenografts [6,7].
Another attempt to inhibit IGF-1R is the use of smallmolecules such
as picropodophylin to inhibit kinase activity [8]. Ubiquitin was dis-
covered in the 1970s to eliminating dysfunctional proteins, but it is
known to be involved in numerous cellular processes like DNAal Societies. Published by Elsevier
ajun@sdu.edu.cn (J. Du).repair, cell cycle, gene expression, regulation of signaling and pro-
tein internalization and trafﬁcking recently. IGF-1R is also a sub-
strate for ubiquitination [9–11], however, there is few research
focusing on ubiquitination of the receptor.
Sunitinib is a small molecule and multi-target tyrosine kinase
inhibitor, approved for treating the advanced and/or metastatic re-
nal cell carcinoma and imatinib-resistant gastrointestinal stromal
tumor (GIST). Sunitinib inhibits vascular endothelial growth factor
receptors (VEGFR of 1, 2 and 3) [12] and the platelet-derived
growth factor receptors (PDGFR in-a and-b) [12,13]. These recep-
tors are implicated in angiogenesis and tumor progression [14–
16]. In addition, sunitinib could inhibit colony-stimulating factor
1 receptor [17], stem-cell factor receptor [14], fms-like tyrosine ki-
nase 3 [18], and glial cell line-derived neurotrophic factor [19],
which play important roles in vascular endothelial cell growth
and migration, vascular permeability, pericyte recruitment, lym-
phangiogenesis and tumor cells survival [20]. However, there is
no any research focused on sunitinib wether inhibits the IGF-1R
tyrosine kinase or not.
In this study, we aim to investigate the effects of sunitinib on
IGF-1R cell signaling transduction. Especially we focus on whetherB.V. Open access under CC BY-NC-ND license.
Fig. 1. IGF-1 receptor is activated by IGF-1. HEK293 cells plated into 24-well plates
were stimulated with 50 ng/ml IGF-1 for 0, 2, 5, 10, 30 and 60 min after serum
starvation for 24 h. IGF-1R was phosphorylated at tyrosine residues Y1131 from
2 min to 60 min in response to IGF-1 stimulation. Simultaneously, themain signaling
proteins, ERK was phosphorylated from 5 min and max at 5 to 10 min whereas Akt
maximum at 30 min. The experiments were performed three times indepently.
2 H. Shen et al. / FEBS Open Bio 2 (2012) 1–5sunitinib could inhibit the phosphorylation and induce the ubiqui-
tination or not.
2. Materials and methods
2.1. Reagents
Anti-IGF-1R, anti-MDM2 and anti-ubiquitin antibodies were
purchased from Santa Cruz Biotechnology Inc. The antibodies of
phospho-IGF-1R tyrosine 1311, phosph-MAPK and phosph-Akt
were from cell signaling Technology. Sunitinib (sutent11248) was
from Pﬁzer Inc. All other reagents were from Sigma.
2.2. Cell cultures
HEK293 cells were cultured in Dulbecco’s modiﬁed Eagle’s med-
ium with sodium supplemented with 10% FBS.
2.3. Transient transfection
The HEK293 cells were put at 80–90% conﬂuent density in 6-
well plates, which was transiently transfected with 4 lg/ml DNA
plasmids containing Mdm2 (HA-MDM2) using Lipofectamine
2000 (Invitrogen). After 24 h, the transfected cell were split into
24-well plates and cultured at serum free medium for another
24 h. Cells then were stimulated with 50 ng/ml IGF-1 and/or
2.5 nM sunitinib. Protein extracts were prepared for immunopre-
cipitation or Western blot.
2.4. Small Interfering RNA
Mdm2 siRNA targeting human MDM2 mRNA (50-AAG CCA UUG
CUU UUG AAG UUA-30) supplied by Dharmacon. siRNA (300 pmol)
was transfected into cells using RNAimax reagent (Invitrogen)
according to the instructions of the manufacturer. A nonsilencing
RNA duplex (50-AAUUCUCCGAACGUGUCACGU-30), (Dharmacon)
was used as a control.
2.5. Immunoprecipitation
The isolated cells were lysed with IP lysis buffer supplied by
Invitrogen, using 500 ll lysis buffer with 10 mM N-ethylmalei-
mide, 50 lMMG132, and protease inhibitor cocktail tablet (Roche)
per well in the 6-well plates. One microgram antibody were added
to each sample and incubated for 3 h at 4 C on a rocker platform.
Then ﬁfteen microliters of Dynabeads Protein G were added. After
overnight incubation at 4 C on a rocker platform, the immunopre-
cipitated complexes were collected by magnet(Invitrogen). The
pellet was washed thrice with IP lysis buffer and then dissolved
in a sample buffer for SDS–PAGE whereupon the samples were
heated for 10 min at 95 C and further analyzed by western blot.
2.6. SDS–PAGE and western blotting
Protein samples were dissolved in a sample buffer containing
1 mM b-mercapethnol. Samples were analyzed by SDS–PAGE with
a 12% separation gel. After SDS–PAGE, the proteins were transferred
to nitrocellulosemembranes (GEHealthcare) at 4 C for 1 h and then
blocked for 1 h at room temperature in a solution of 5% (w/v)
skimmed milk powder and 0.02% (w/v) Tween 20 in PBS, pH 7.5.
Incubation with appropriate primary antibodies overnight at 4 C.
Thiswas followedbywasheswith PBSTand incubationwith ahorse-
radish peroxidase-labeled secondary antibody (Pierce) for 1 h at
room temperature. The detection was made with ECL (Pierce). The
ﬁlms were exposured; and then developed and ﬁxed.3. Results
3.1. IGF-1R signaling is activated in response to ligand stimulation
HEK293 cells were stimulated with 50 ng/ml IGF-1 for 2, 5, 10,
30 and 60 min after 24 h serum starvation. As expected, IGF-1R
was phosphorylated at tyrosine residues Y1131 from 2 min to
60 min in response to IGF-1 stimulation (Fig. 1). Simultaneously,
we used the same samples to detect the phosphorylation of the
main signaling proteins, Akt and ERK. We found that ERK was
phosphorylated from 5 min and max at 5 to 10 min and Akt was
phosphorylated maximum at 30 min, as been shown in Fig. 1.
3.2. IGF-1R tyrosine phosphorylation is inhibited by sunitinib
As shown in Fig. 2, following serum starvation for 24 h, cells
were treated 50 ng/ml IGF-1 or ﬁrst treated 2.5 nM sunitinib for
1 h and then simulated with 50 ng/ml IGF-1 for 2, 5, 10, 30 and
60 min. Compared with single IGF-1, sunitinib signiﬁcantly de-
creased the IGF-1R tyrosine phosphorylation, even there was no
phosphorylation after IGF-1 stimulation for 1 h.
3.3. Sunitinib inhibits IGF-1R signaling transduction
HEK293 cells were treated as above. To detect whether suniti-
nib affects the IGF-1R signaling, we used IGF-1 induced Akt and
ERK phosphorylation as a measurement of PI3K and MAPK path-
ways activation, seperately. As can be seen in Fig. 2, Akt and ERK
proteins were phosphorylated after IGF-1 stimulation without sun-
itinib. However, in cells treated with with 2.5 nM sunitinib for 1 h
and then simulated with 50 ng/ml IGF-1, both Akt and ERK phos-
phorylation was largely reduced, indicating that sunitinib inhibits
the IGF-1R signaling pathway.
3.4. IGF-1 down-regulates IGF-1R and induces IGF-1R ubiquitination
To determine IGF-1R degradation, HEK293 cells were treated
100 ng/ml IGF-1 in serum free medium for 1, 3, 6, 12 and 24 h.
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Fig. 2. Sunitinib inhibits IGF-1R signaling transduction. Following serum starvation for 24 h, HEK293 cells were treated with 50 ng/ml IGF-1 or ﬁrst treated with 2.5 nM
sunitinib for 1 h and then simulated with 50 ng/ml IGF-1 for 0, 2, 5, 10, 30 and 60 min. Compared with single IGF-1, sunitinib signiﬁcantly decreased the IGF-1R tyrosine
phosphorylation. Both Akt and ERK phosphorylation was largely reduced. The phosphorylation signals were quantiﬁed by pIGF-1R, pAkt and pERK versus total IGF-R, Akt and
ERK of western blotting. Data was shown as means and SEMs. The results were from 3 independent experiments.
H. Shen et al. / FEBS Open Bio 2 (2012) 1–5 3We found that IGF-1 obviously down regulated the IGF-1R expres-
sion (Fig. 3).
For analysis the ubiquitination, HEK293 cells split in 6-well
plates were simulated with 100 ng/ml IGF-1 for 10 min after
24 h serum starvation. Following IGF-1 stimulation, cells were
harvested with IP buffer (see Section 2). The IGF-R antibody
was used for immunoprecipitation, and immunoblotting with
ubiquitin antibody. As shown in Fig. 4, IGF-1 could induce obvi-
ous IGF-1R ubiquitination at 10 min compared with control (only
serum free, no stimulation), indicating IGF-1 down-regulates theFig. 3. IGF-1R is down-regulated by IGF-1 and sunitinib. (a) IGF-1R is degradated after
medium for 1, 3, 6, 12 and 24 h. IGF-1 obviously down regulated the IGF-1R expression ac
were treated with with 100 ng/ml IGF-1 or 5 nM sunitinib in serum free medium for 1,
expression, but its effects was postpone. The signals were quantiﬁed by densitometry anIGF-1R by increasing the receptor degradation dependent on
ubiquitination.
3.5. Sunitinib induces IGF-1R degradation and ubiquitination
HEK293 cells were treated as above. Sunitinib (5 nM) also down
regulated the IGF-1R expression, but its effects was postpone in
comparison with IGF-1 and there was no obvious degradation until
12 h later. For the ubiquitination, cells were treated with 100 ng/ml
IGF-1 or 5 nM sunitinib for 10 min after 24 h serum starvation, and0
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IGF-1 stimulation. HEK293 cells were treated with 100 ng/ml IGF-1 in serum free
cording to stimulation time. (b) IGF-1R is down-regulated by sunitinib. HEK293 cells
3, 6, 12 and 24 h. Compared with IGF-1, Sunitinib also down regulated the IGF-1R
d data was presented as means and SEMs, Which was from 3 different experiments.
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Fig. 4. Sunitinib induces IGF-1R ubiquitination dependent on MDM2. (a) IGF-1 and sunitinib mediate IGF-1R ubiquitination. For analysis the ubiquitination, HEK293 cells
split in 6-well plates were simulated with 100 ng/ml IGF-1 1 or 5 nM sunitinib for 10 min after serum starvation for 24 h. Following stimulation, cells were harvested with IP
buffer. The IGF-R antibody was used for immunoprecipitation, and immunobloting with ubiquitin antibody. Both IGF-1 and sunitinib could induce obviously the IGF-1R
ubiquitination at 10 min compared with C (control, only serum free, no stimulation); however, ubiquitination induced by sunitinib was weaker than that induced by IGF-1.
(b) HEK293 cells were immunoprecipitated with IGF-1R antibody and detected with MDM2 antibody when stimulation with 5 nM sunitinib for 10 min after serum starvation
for 24 h. There is MDM2 signal compared with C (control, only serum free, no stimulation). (c) The efﬁciency of transient transfection. C is the non-transfected cells. (d)
Sunitinib mediate IGF-1R ubiquitination dependent on MDM2. HEK293 cells were transiently transfected with human HA-MDM2 (+MDM2) or siRNA to MDM2 (MDM2).
Following 24 h serum starvation, cells were stimulated with 10 nM sunitinib for 10 min. IGF-1R was immunoprecipitated and analyzed for ubiquitination. In over-expressed
MDM2 cells IGF-1R was ubiquitinated more than that in mock-transfected cells (control), in response to 10 nM sunitinib. Further more, there was nearly no ubiquination in
MDM2 cells. These results mean that sunitinib mediates IGF-1R dependent on MDM2. The ubiquitins signals were quantiﬁed by densitometry and data was expressed as
means and SEMs. These experiments were repeated at least 3 times.
4 H. Shen et al. / FEBS Open Bio 2 (2012) 1–5then immunoprecipitation and immunobloting as above. Sunitinib
could induce the IGF-1R ubiquitination after 10 min stimulation as
we can see in Fig. 4. However, ubiquitination induced by sunitinib
was weaker than that induced by IGF-1, whichmaybe due to differ-
ent types of ubiquitination.
3.6. Sunitinib induces IGF-1R ubiquitination dependent on MDM2
Considering sunitinib mediates IGF-1R ubiquitination, we were
interested in if it was dependent on MDM2 as a ligand. To perform
these experiments, ﬁrstly, HEK293 cells were immunoprecipitated
with IGF-1R antibody and detected with MDM2 antibody after sun-
itinib stimulation, then cells were transiently transfected with hu-
man HA-MDM2 (+MDM2) or siRNA to MDM2 (MDM2).
Following 24 h serum starvation, cells were stimulated with
10 nM sunitinib for 10 min. IGF-1R was immunoprecipitated as
above and analyzed for ubiquitination. As shown in Fig. 4b, MDM2
combined to IGF-1R with sunitinib stimulation. In over-expressed
MDM2 cells IGF-1R was ubiquitinated more than that in mock-
transfected cells (control), in response to 10 nM sunitinib. Further-
more, there was nearly no ubiquination in –MDM2 cells. These re-
sults mean that sunitinib mediates IGF-1R dependent on MDM2.
The ubiquitination of IGF-1R in normal, +MDM2 and MDM2 cells
were shown in Fig. 4d. The MDM2 transfection efﬁciency was also
presented in Fig. 4c.
4. Discussion
The IGF-1R is activated by the binding of the ligands IGF-1 and
IGF-2, which has a nearly 20-fold higher afﬁnity for IGF-1 than for
IGF-2. After the binding of these ligands to the receptor a-subunit,structural changes in the IGF-1R result in the phosphorylation and
activation of tyrosine kinases. IGF-1R activation initiates lots of
downstream cascade. These reactions mainly involve bellow path-
ways including PI3K (Phosphatidylinositol-3-Kinase), Akt and
mTOR; and Ras, Raf and MAPK [21,22]. As we showed, IGF-1 bind-
ing to IGF-1R results in phosphorylation of tyrosine residues, and
further induces ERK and Akt phosphorylation which are the major
proteins involving in IGF-1R signaling transduction.
The activation of IGF-1R pathways led to oncogenic transforma-
tion, growth and survival of cancer cells [23]. Therefore, inhibitionof
this signaling transduction will contribute to cancer therapy. Re-
cently, there are lots of researches focused on the IGF-1R, such as
several drugs targeting to IGF-1R have been approved to clinical tri-
als. Sunitinib as a receptor tyrosine kinases inhibitor, however, has
never beenused to inhibit the IGF-1R signaling. In thepresent exper-
iments, sunitinib obviously reduced the IGF-1R tyrosine phosphory-
lation. Further, it also inhibits the IGF-1R signaling transduction
such as inhibiting phosphorylation of Akt and ERK. Take these data
together, we conclude that sunitinib not only inhibit the VEGFR
and PDGFR, but also IGF-1R, whichmeans sunitinib is a very power-
fulmulti-targets drug for cancer therapy. Our research broadens the
applied area of sunitinib and beneﬁts the cancer patients.
Ubiquitin is not only for labeling of proteins destined for degra-
dation but also for activation of many other enzymes and signal
proteins. More and more research shed light on ubiquitination,
especially on IGF-1R [8–11]. Our data shows that both IGF-1 and
sunitinib mediate IGF-1R degradation and ubiquitination. IGF-1
and sunitinib obviously down-regulate the IGF-1R expression
according to stimulation time; however IGF-1 is stronger than sun-
itinib. We also found that IGF-1 and sunitinib induced the
ubiquitination.
H. Shen et al. / FEBS Open Bio 2 (2012) 1–5 5Ubiquitination induced by sunitinib was weaker than that in-
duced by IGF-1, which maybe due to different types of
ubiquitination.
Several E3 ligases, such as Mdm2 [9], Nedd 4 [11] and c-cbl [24],
have been demonstrated to mediate ubiquitins binding to lysine
residues in IGF-1R. Different ligands binding to IGF-1R will active
different downsteam reactions. On IGF-1 binding, both Mdm2
and c-Cbl are involving in IGF-IR ubiquitination, which mediate
in variable pathway [9,24]. In Mdm2-mediated ubiquitination,
reactions occur after stimulation with a low concentration of
IGF-I and b-arrestins as an adapter [10], whereas c-Cbl required
high concentrations. Our study demonstrated sunitinib mediated
ubiquitination dependent on E3 ligase MDM2. The transfection
experiments supported our ﬁndings. In +MDM2 cells IGF-1R was
ubiquitinated more than that in mock-transfected cells (control),
whereas nearly no ubiquination in MDM2 cells. The results of
IGF-1R ubiquitination in normal, +MDM2 and MDM2 cells were
shown in Fig. 4d.
In summary, we ﬁnd that sunitinib not only inhibit the cell sig-
naling transduction of IGF-1R, but also induce receptor ubiquitina-
tion which dependent on MDM2. These shed lights on sunitinib
could be used for IGF-1R over-expressed cancers such as prostate,
breast, colorectal and NSCLC cancers and so on.
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